CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...
For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.
Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the ...
Cat­a­lyst Phar­ma­ceu­ti­cals’ con­tro­ver­sial $375,000 rare au­toim­mune dis­ease drug now won’t face gener­ic com­pe­ti­tion from Te­va un­til Feb. 25, 2035, thanks to a ...
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva ...
Prior to filing its lawsuit, Catalyst in January of 2023 revealed that Teva had filed for approval of a generic version of Firdapse. Notably, the Israeli-American pharma said it planned to market ...
This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of FIRDAPSE ® ...